Indications for FLUZONE QUADRIVALENT:
Adults and Children:
<6mos: not established. Give by IM inj once in the anterolateral thigh (6–11mos) or in the deltoid (≥12mos). If 2 doses, give at least 4 weeks apart. 6–35mos: not previously vaccinated or unknown: 2 doses (0.25mL and/or 0.5mL); previously vaccinated: 1 or 2 doses (0.25mL and/or 0.5mL) depending on vaccination history as per annual ACIP recommendation. 36mos–8yrs: not previously vaccinated or unknown: 2 doses (0.5mL); previously vaccinated: 1 or 2 doses (0.5mL) depending on vaccination history as per annual ACIP recommendation. ≥9yrs: 1 dose (0.5mL).
Allergy to egg proteins. Life-threatening reaction to any previous flu vaccine.
Use current formulation only. Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Immunosuppressed. Have epinephrine inj (1:1000) available. Pregnancy (Cat.C for High-Dose; Cat.B for Intradermal Quadrivalent). Nursing mothers.
Immunosuppressants: may get suboptimal response.
Local reactions (eg, pain, tenderness, swelling, erythema), malaise, headache, myalgia, irritability.
Fluzone, Fluzone Quadrivalent prefilled syringe (0.25mL, 0.5mL)—10; Single-dose vial (0.5mL)—10; Fluzone, Fluzone Quadrivalent multi-dose vial (5mL)—1 (contains thimerosal); Fluzone High-Dose prefilled syringe (0.5mL)—10; Fluzone Intradermal Quadrivalent single-dose prefilled microinjection system (0.1mL)—10